Upcoming Event: The Antibody Series 2026 x KACTUS
We’re heading to Évora, Portugal for The Antibody Series 2026 hosted by FairJourney Biologics, taking place September 16–18, 2026. This invitation-only conference brings together leading experts from industry, academia, and venture capital to explore emerging science, technologies, and strategies shaping the future of antibody discovery and development.
The 2026 program reflects the rapid pace of innovation across antibody science and engineering, with discussions spanning natural antibody repertoires, computational design, novel engineering strategies, next-generation modalities, and therapeutic development.
What is The Antibody Series?
Hosted by FairJourney Biologics, The Antibody Series is a focused conference dedicated to advancing antibody discovery and development through scientific exchange, collaboration, and knowledge-sharing. The meeting brings together world-renowned experts, researchers, and industry leaders to share groundbreaking work, explore cutting-edge technologies and applications, and discuss emerging trends shaping the antibody field.
The 2026 program reflects the rapid pace of innovation across antibody science and engineering, with a particular focus on how natural antibody repertoires, computational design, and novel engineering strategies are transforming the discovery and development of antibody therapeutics. By fostering communication between academic and industry leaders, The Antibody Series creates an environment for meaningful scientific discussion and collaboration around the technologies and approaches driving the next generation of antibody medicines.
Event Overview
Venue: Évora, Portugal
Dates: September 16–18, 2026
Format: Invitation-only conference
- Conference Day 1: Wednesday, September 16, 2026
- Conference Day 2: Thursday, September 17, 2026
- Conference Day 3: Friday, September 18, 2026
Event Schedule
The Antibody Series 2026 will take place over three days, bringing together leaders from industry and academia for focused discussions on the latest advances in antibody discovery, engineering, and therapeutic development. The program is designed to encourage deep scientific exchange, with presentations, panel discussions, real-world case studies, and opportunities to connect with peers across the antibody community.
This year’s scientific program will explore how natural antibody repertoires, computational design, and novel engineering strategies are transforming the discovery and development of therapeutic antibodies. Attendees can expect discussions around emerging technologies, new approaches to antibody design and engineering, and some of the most challenging questions facing antibody drug development today.
The three-day meeting will also provide opportunities for networking and collaboration among scientists and industry leaders working to advance the next generation of antibody therapeutics.
About KACTUS
KACTUS excels in crafting and producing an array of superior-grade, highly active recombinant proteins and enzymes, catering to diverse sectors like antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. Our expansive catalog, boasting over 3,000 recombinant proteins, encompasses a wide spectrum of targets, species, tags, and labels, each thoughtfully chosen to address the specific, unmet needs of scientists engaged in drug development. The hallmark of our product selection process is a rigorous emphasis on exceptional quality and a steadfast commitment to ensuring reliable supply, thereby upholding the highest standards of excellence and client satisfaction.
